You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201381 - 201390 of 207712 results
  1. Increasing CO2 Conversion to Fuel with Optical Thermal Management in Concentrated Solar Reactors New Dual-Stage Solar Reactor Design for Reduction of Carbon Dioxide to Fuels

    SBC: DIMENSIONAL ENERGY, INC.            Topic: 22c

    Direct utilization of concentrated sunlight provides a low-cost source of energy for photocatalytic chemical reactions that convert carbon dioxide to fuels and chemicals. However, the usable portion of the solar spectrum for chemical reactions is small (generally

    SBIR Phase I 2020 Department of Energy
  2. Label-free platform for applications in drug discovery

    SBC: VST LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The primary sequelae resulting from radical mastectomy and sentinel lymph node removal during the treatment of breast cancer is the development of lymphedema in related limbs. Estimates of the frequency of post-cancer lymphedema range from 20%-90%, depending upon the metrics used to measure development of the condition. There is significant social and monetary ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Oral vaccine delivery of recombinant subunit vaccines for animal diseases

    SBC: VST LLC            Topic: HSB0141002

    Wildlife are a reservoir of diseases affecting both humans and domestic animals. These wildlife reservoirs represent a potential threat to public health, serving as a continuous and difficult to eradicate source of infection for zoonotic diseases, but may also represent a significant economic threat to US agriculture. In particular, wild ruminants including white-tail deer may harbor vector-bo ...

    SBIR Phase I 2014 Department of Homeland Security
  4. IGF::OT::IGF- DEVELOPMENT OF INULIN ACETATE-BASED ADJUVANT.

    SBC: VST LLC            Topic: NIAID

    This project aims to evaluate and compare a new soluble inulin microparticle adjuvant along with approved human adjuvants alum and ISA-51VG (Seppic) in a vaccine study utilizing the company?s Rift Valley Fever virus (RVFV) recombinant protein subunit vaccine. The new adjuvant may have potential commercial applications for both human and veterinary vaccines for Rift Valley Fever. PUBLIC HEALTH RELE ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Oral vaccine delivery of recombinant subunit vaccines for animal diseases

    SBC: VST LLC            Topic: HSB0141002

    Wildlife are a reservoir of diseases affecting both humans and domestic animals. These wildlife reservoirs represent a potential threat to public health, serving as a continuous and difficult to eradicate source of infection for zoonotic diseases, but may also represent a significant economic threat to US agriculture. In particular, wild ruminants including white-tail deer may harbor vector-bo ...

    SBIR Phase II 2015 Department of Homeland Security
  6. Developing Pre-Consumer Waste as Low-Cost Cricket Feed for Small Farming Operations

    SBC: MIGHTY CRICKET, INC            Topic: 812

    PROJECT SUMMARY Title: Developing Pre-Consumer Waste as Low-Cost Cricket Feed for Small Farming Operations PD: Schlafly Sarah Company: Mighty Cricket      Advisor: Morales Ramos Juan A. Institution: USDA-ARS (unfunded in phase I)    Advisor: Rojas Guadalupe M. Institution: USDA-ARS (unfunded in phase I) The goal of this project to develop a s ...

    SBIR Phase I 2023 Department of Agriculture
  7. Aerosolized vitamin A impact on lung maturation and hyperoxic neonatal lung injury

    SBC: ADVENT THERAPEUTICS INC            Topic: NHLBI

    Advent Therapeutics IncAdventis a biotech company focusing on the developmentreformulation and optimized delivery of legacy drugs to address serious unmet medical needs in underserved patient populationsAdvent is developing an aerosol formulation of its proprietary optimizedwater miscible vitamin AvitApalmitate for non invasiveinhaleddelivery of the drug to preterm infantsOur innovative inhaled vi ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Aerosolized Vitamin A: Impact on Neonatal Lung Maturation, Hyperoxic Lung Injury and Bronchopulmonary Dysplasia

    SBC: ADVENT THERAPEUTICS INC            Topic: NHLBI

    Advent Therapeutics Inc. (Advent) is a biotech company focusing on the development, reformulation and optimized delivery of legacy drugs to address serious unmet medical needs in the underserved neonatal and pediatric patient populations. Advent is developing an aerosol formulation of its proprietary, optimized water miscible vitamin A (vitA) palmitate for non-invasive (inhaled) delivery to preter ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Advancing Small Molecule Read Through Compounds to Prevent and/or Treat Heritable Pulmonary Artery Hypertension

    SBC: ADVENT THERAPEUTICS INC            Topic: NHLBI

    Advent Therapeutics is a company that develops new therapies for neonatal, pediatric, and Orphan Drug “niche” markets to address serious unmet medical needs. Our team proposes early stage development of a new treatment for hereditable pulmonary arterial hypertension (hPAH), a rare, hereditary disorder that involves progressive elevation of pulmonary arterial pressures, right heart failure, and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation

    SBC: ADVENT THERAPEUTICS INC            Topic: NHLBI

    Advent Therapeutics (Advent) is a biotech focusing on novel approaches to reformulate and optimize delivery of legacy drugs with proven efficacy to address unmet medical needs of specific underserved and orphan patient populations. Advent is developing an aerosol formulation of its proprietary, optimized water miscible vitamin A (vitA) palmitate for non-invasive (inhaled) delivery to preterm infan ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government